Corventum

Executive Summary

Corventum is a San Francisco-based private company specializing in cardiovascular medical devices and digital health solutions. Founded in 2017, the company has reached the commercial stage with a team of 10-50 employees, indicating it has developed products that are ready for market or already generating revenue. Corventum focuses on monitoring and managing cardiovascular diseases, a large and growing market driven by aging populations and increasing prevalence of heart conditions. The company's integrated approach combines hardware and software, positioning it to capture value across the care continuum. Although specific financials and product details are not publicly available, Corventum's commercial-stage status suggests it has achieved key milestones such as regulatory clearances or initial market traction. The cardiovascular device market is projected to exceed $70 billion by 2027, and digital health adoption is accelerating. Corventum is well-positioned to benefit from these trends, particularly if it can secure partnerships with healthcare providers or expand its product portfolio. However, as a private entity with limited disclosure, risks include competition from larger players and execution challenges in scaling sales.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation cardiac monitor75% success
• Q3 2026Strategic partnership with a major hospital network for pilot deployment60% success
• TBDSeries B funding round to scale commercialization80% success